<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31355778</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets.</ArticleTitle><Pagination><StartPage>3578</StartPage><EndPage>3593</EndPage><MedlinePgn>3578-3593</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI124481</ELocationID><ELocationID EIdType="pii" ValidYN="Y">124481</ELocationID><Abstract><AbstractText>TAR DNA-binding protein 43 kDa (TDP-43), encoded by TARDBP, is an RNA-binding protein, the nuclear depletion of which is the histopathological hallmark of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder affecting both upper and lower motor neurons. Besides motor symptoms, patients with ALS often develop nonneuronal signs including glucose intolerance, but the underlying pathomechanism is still controversial, i.e., whether it is impaired insulin secretion and/or insulin resistance. Here, we showed that ALS subjects reduced early-phase insulin secretion and that the nuclear localization of TDP-43 was lost in the islets of autopsied ALS pancreas. Loss of TDP-43 inhibited exocytosis by downregulating CaV1.2 calcium channels, thereby reducing early-phase insulin secretion in a cultured &#x3b2; cell line (MIN6) and &#x3b2; cell-specific Tardbp knockout mice. Overexpression of CaV1.2 restored early-phase insulin secretion in Tardbp knocked-down MIN6 cells. Our findings suggest that TDP-43 regulates cellular exocytosis mediated by L-type voltage-dependent calcium channels and thus plays an important role in the early phase of insulin secretion by pancreatic islets. Thus, nuclear loss of TDP-43 is implicated in not only the selective loss of motor neurons but also in glucose intolerance due to impaired insulin secretion at an early stage of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Araki</LastName><ForeName>Kunihiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araki</LastName><ForeName>Amane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Daiyu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumoto</LastName><ForeName>Takako</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Akitoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikumi</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Kaori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishigaki</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamichi</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsunekawa</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seino</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cell Signaling, National Institute for Physiological Sciences, Okazaki, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Shihomi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tominaga</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cell Signaling, National Institute for Physiological Sciences, Okazaki, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohara-Imaizumi</LastName><ForeName>Mica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishiguro</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enomoto</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muramatsu</LastName><ForeName>Shin-Ichi</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Division of Neurological Gene Therapy, Jichi Medical University, Shimotsuke, Tochigi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Gene &amp; Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Center, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514350">CACNA1C protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="Y">Exocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005951" MajorTopicYN="N">Glucose Tolerance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078790" MajorTopicYN="N">Insulin Secretion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007515" MajorTopicYN="N">Islets of Langerhans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Calcium channels</Keyword><Keyword MajorTopicYN="N">Insulin</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> SM owns equity in Gene Therapy Research Institution, a gene therapy company that commercializes the use of AAV vectors for gene therapy applications.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31355778</ArticleId><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="doi">10.1172/JCI124481</ArticleId><ArticleId IdType="pii">124481</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2011;8(4):262&#x2013;274. doi: 10.1159/000321547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000321547</ArticleId><ArticleId IdType="pmc">PMC3214943</ArticleId><ArticleId IdType="pubmed">21124004</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics. 2015;12(2):352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases. J Biol Chem. 2009;284(33):22059&#x2013;22066. doi: 10.1074/jbc.M109.012195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.012195</ArticleId><ArticleId IdType="pmc">PMC2755930</ArticleId><ArticleId IdType="pubmed">19535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012;287(33):27335&#x2013;27344. doi: 10.1074/jbc.M112.359000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.359000</ArticleId><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111(12):E1121&#x2013;E1129. doi: 10.1073/pnas.1322641111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20(7):1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Quick DT, Greer M. Pancreatic dysfunction in patients with amyotrophic lateral sclerosis. Neurology. 1967;17(2):112&#x2013;116. doi: 10.1212/WNL.17.2.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.17.2.112</ArticleId><ArticleId IdType="pubmed">6066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto F, Kitamura A, Koto A, Kataoka K, Atsuji H. Abnormal insulin secretion in amyotrophic lateral sclerosis. J Neurol Sci. 1972;16(2):201&#x2013;207. doi: 10.1016/0022-510X(72)90089-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(72)90089-5</ArticleId><ArticleId IdType="pubmed">5037443</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes ET, Perurena OH, Festoff BW, Jorgensen R, Moore WV. Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci. 1984;63(3):317&#x2013;324. doi: 10.1016/0022-510X(84)90154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(84)90154-0</ArticleId><ArticleId IdType="pubmed">6374040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1-2):166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Xu Y, Hu X, Choi B, Tong Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis. 2010;48(11):628&#x2013;634. doi: 10.1002/dvg.20672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvg.20672</ArticleId><ArticleId IdType="pmc">PMC3641578</ArticleId><ArticleId IdType="pubmed">20824628</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulla V, et al. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J. 2003;22(15):3844&#x2013;3854. doi: 10.1093/emboj/cdg389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdg389</ArticleId><ArticleId IdType="pmc">PMC169062</ArticleId><ArticleId IdType="pubmed">12881419</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JT, Huang L, Keyser BM, Zhuang H, Clarkson CW, Li M. Role of high-voltage-activated calcium channels in glucose-regulated beta-cell calcium homeostasis and insulin release. Am J Physiol Endocrinol Metab. 2005;289(5):E900&#x2013;E908. doi: 10.1152/ajpendo.00101.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00101.2005</ArticleId><ArticleId IdType="pubmed">15956052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem. 2011;286(2):1204&#x2013;1215. doi: 10.1074/jbc.M110.190884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.190884</ArticleId><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyburn L, Moussa CE. TDP-43 overexpression impairs presynaptic integrity. Neural Regen Res. 2016;11(12):1910&#x2013;1911. doi: 10.4103/1673-5374.195272.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.195272</ArticleId><ArticleId IdType="pmc">PMC5270420</ArticleId><ArticleId IdType="pubmed">28197178</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskiewicz K, et al. HDAC6 is a Bruchpilot deacetylase that facilitates neurotransmitter release. Cell Rep. 2014;8(1):94&#x2013;102. doi: 10.1016/j.celrep.2014.05.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.05.051</ArticleId><ArticleId IdType="pubmed">24981865</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GA, Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J Neurosci. 2013;33(4):1741&#x2013;1752. doi: 10.1523/JNEUROSCI.4003-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4003-12.2013</ArticleId><ArticleId IdType="pmc">PMC6618732</ArticleId><ArticleId IdType="pubmed">23345247</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Hazelett DJ, Stewart JA, Morton DB. Motor neuron expression of the voltage-gated calcium channel cacophony restores locomotion defects in a Drosophila, TDP-43 loss of function model of ALS. Brain Res. 2014;1584:39&#x2013;51. doi: 10.1016/j.brainres.2013.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.11.019</ArticleId><ArticleId IdType="pmc">PMC4031311</ArticleId><ArticleId IdType="pubmed">24275199</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, Izaurieta P, Fritz E, Alvarez FJ. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Cell Biochem. 2012;113(11):3301&#x2013;3312. doi: 10.1002/jcb.24234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.24234</ArticleId><ArticleId IdType="pmc">PMC3886915</ArticleId><ArticleId IdType="pubmed">22740507</ArticleId></ArticleIdList></Reference><Reference><Citation>Saffer D, Morley J, Bill PL. Carbohydrate metabolism in motor neurone disease. J Neurol Neurosurg Psychiatry. 1977;40(6):533&#x2013;537. doi: 10.1136/jnnp.40.6.533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.40.6.533</ArticleId><ArticleId IdType="pmc">PMC492758</ArticleId><ArticleId IdType="pubmed">903768</ArticleId></ArticleIdList></Reference><Reference><Citation>Perurena OH, Festoff BW. Reduction in insulin receptors in amyotrophic lateral sclerosis correlates with reduced insulin sensitivity. Neurology. 1987;37(8):1375&#x2013;1379. doi: 10.1212/WNL.37.8.1375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.37.8.1375</ArticleId><ArticleId IdType="pubmed">3614662</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Windrem M, Zappavigna V, Goldman SA. Identification of a conserved 125 base-pair Hb9 enhancer that specifies gene expression to spinal motor neurons. Dev Biol. 2005;283(2):474&#x2013;485. doi: 10.1016/j.ydbio.2005.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2005.04.017</ArticleId><ArticleId IdType="pubmed">15913596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Slit and Semaphorin signaling governed by Islet transcription factors positions motor neuron somata within the neural tube. Exp Neurol. 2015;269:17&#x2013;27. doi: 10.1016/j.expneurol.2015.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.03.024</ArticleId><ArticleId IdType="pmc">PMC4446133</ArticleId><ArticleId IdType="pubmed">25843547</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11(3):286&#x2013;292. doi: 10.1111/j.1464-5491.1994.tb00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.1994.tb00273.x</ArticleId><ArticleId IdType="pubmed">8033528</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 1997;20(10):1562&#x2013;1568. doi: 10.2337/diacare.20.10.1562.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.20.10.1562</ArticleId><ArticleId IdType="pubmed">9314636</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda A, Kuzuya T. The prevalence of low insulin responders to oral glucose load among groups with various patterns of family history of diabetes. Diabet Med. 1996;13(9 Suppl 6):S59&#x2013;S62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8894484</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi S, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig. 2011;2(4):297&#x2013;303. doi: 10.1111/j.2040-1124.2010.00096.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2040-1124.2010.00096.x</ArticleId><ArticleId IdType="pmc">PMC4014971</ArticleId><ArticleId IdType="pubmed">24843502</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412&#x2013;419. doi: 10.1007/BF00280883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00280883</ArticleId><ArticleId IdType="pubmed">3899825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, et al. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2016;3(7):537&#x2013;546. doi: 10.1002/acn3.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.324</ArticleId><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference><Reference><Citation>Udagawa T, et al. FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nat Commun. 2015;6:7098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479014</ArticleId><ArticleId IdType="pubmed">25968143</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi S, et al. 3&#x2019;UTR length-dependent control of SynGAP isoform &#x3b1;2 mRNA by FUS and ELAV-like proteins promotes dendritic spine maturation and cognitive function. Cell Rep. 2017;20(13):3071&#x2013;3084. doi: 10.1016/j.celrep.2017.08.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.100</ArticleId><ArticleId IdType="pubmed">28954225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara-Imaizumi M, et al. ELKS, a protein structurally related to the active zone-associated protein CAST, is expressed in pancreatic beta cells and functions in insulin exocytosis: interaction of ELKS with exocytotic machinery analyzed by total internal reflection fluorescence microscopy. Mol Biol Cell. 2005;16(7):3289&#x2013;3300. doi: 10.1091/mbc.e04-09-0816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e04-09-0816</ArticleId><ArticleId IdType="pmc">PMC1165411</ArticleId><ArticleId IdType="pubmed">15888548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara-Imaizumi M, Nakamichi Y, Tanaka T, Ishida H, Nagamatsu S. Imaging exocytosis of single insulin secretory granules with evanescent wave microscopy: distinct behavior of granule motion in biphasic insulin release. J Biol Chem. 2002;277(6):3805&#x2013;3808. doi: 10.1074/jbc.C100712200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C100712200</ArticleId><ArticleId IdType="pubmed">11751926</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, Nakamichi Y, Nagamatsu S. Insulin/phosphoinositide 3-kinase pathway accelerates the glucose-induced first-phase insulin secretion through TrpV2 recruitment in pancreatic &#x3b2;-cells. Biochem J. 2010;432(2):375&#x2013;386. doi: 10.1042/BJ20100864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20100864</ArticleId><ArticleId IdType="pubmed">20854263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara-Imaizumi M, et al. Imaging analysis reveals mechanistic differences between first- and second-phase insulin exocytosis. J Cell Biol. 2007;177(4):695&#x2013;705. doi: 10.1083/jcb.200608132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200608132</ArticleId><ArticleId IdType="pmc">PMC2064214</ArticleId><ArticleId IdType="pubmed">17502420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, et al. Ethanol induces fluid hypersecretion from guinea-pig pancreatic duct cells. J Physiol (Lond) 2003;551(Pt 3):917&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2343300</ArticleId><ArticleId IdType="pubmed">12847207</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XG, et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol Ther. 2006;13(1):160&#x2013;166. doi: 10.1016/j.ymthe.2005.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2005.08.009</ArticleId><ArticleId IdType="pubmed">16182609</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes CJ, Halban PA. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway. J Cell Biol. 1987;105(1):145&#x2013;153. doi: 10.1083/jcb.105.1.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.105.1.145</ArticleId><ArticleId IdType="pmc">PMC2114904</ArticleId><ArticleId IdType="pubmed">3301864</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki T, et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes. 2005;54(4):1056&#x2013;1063. doi: 10.2337/diabetes.54.4.1056.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.4.1056</ArticleId><ArticleId IdType="pubmed">15793244</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibasaki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104(49):19333&#x2013;19338. doi: 10.1073/pnas.0707054104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0707054104</ArticleId><ArticleId IdType="pmc">PMC2148290</ArticleId><ArticleId IdType="pubmed">18040047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;87(7):1327&#x2013;1338. doi: 10.1016/S0092-8674(00)81827-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81827-9</ArticleId><ArticleId IdType="pubmed">8980238</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>